• Policy
• We will do our best to compensate for Paxlovid side effects
• by Lee, Jeong-Hwan Nov 10, 2022 05:45am

• Policy
• Drug prices should be raised if RWD show high effect
• by Lee, Tak-Sun Nov 9, 2022 05:47am

• Policy
• Ex officio adjustment reduces prices of Faslodex and Acelex
• by Kim, Jung-Ju Nov 8, 2022 05:43am

• Policy
• It has been four years since Eucept was released
• by Lee, Hye-Kyung Nov 7, 2022 06:06am

• Policy
• We will continue to strengthen cooperation with the HIRA
• by Kim, Jung-Ju Nov 7, 2022 06:05am

• Policy
• No budget set to compensate increasing Paxlovid AE reports
• by Lee, Jeong-Hwan Nov 7, 2022 06:05am

• Policy
• Strepto formulations negotiated at a rate of 20%
• by Lee, Tak-Sun Nov 4, 2022 05:39am

• Policy
• Government-Pharmaceutical Consultation on Acetaminophen
• by Lee, Jeong-Hwan Nov 4, 2022 05:39am

• Policy
• Reimb standards set for first RET-targeted Retevmo
• by Lee, Tak-Sun Nov 4, 2022 05:39am

• Policy
• The self-sufficiency of national essential drugs has begun
• by Lee, Hye-Kyung Nov 4, 2022 05:38am